Kolexia
Kalbacher Elsa Oncologie médicale
Kalbacher Elsa
Oncologie médicale
Centre Jean-Perrin
Clermont-Ferrand, France
171 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Récidive tumorale locale Carcinomes Embolie Embolie pulmonaire Sarcomes Léiomyosarcome Tumeurs embryonnaires et germinales

Collaborateurs

Voir plus
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France
Berton Dominique
Berton Dominique
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Pautier Patricia
Pautier Patricia
Gustave-Roussy, Villejuif, France

Industries

Voir plus
AstraZeneca
7 collaboration(s)
Dernière en 2021
GSK
6 collaboration(s)
Dernière en 2023
PUBLICLIN
3 collaboration(s)
Dernière en 2022
Seagen
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
STARTER: A National, Multicenter, Phase III Randomized Controlled Trial to Assess the Impact of a One-year Supervised Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Essai Clinique (Centre Léon-Bérard)   20 février 2024
EXOSARC: Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)
Essai Clinique (Centre Georges-François Leclerc)   11 décembre 2023
GYNET: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Essai Clinique (NETRIS Pharma)   24 novembre 2023
REGOBONE: A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Essai Clinique (Unicancer)   06 novembre 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
British journal of cancer   01 novembre 2023
288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Abstract Book of the ESMO Asia Congress 2023, 1-3 December 2023   01 novembre 2023
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Essai Clinique (Pfizer)   26 octobre 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   15 octobre 2023
1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
815P Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023